FDA OKs BrainLab radiosurgery planning software

TriMed Staff | | Health Imaging | Oncology Imaging
BrainLab has received 510(k) clearance from the FDA for its HybridArc radiosurgery planning software.

HybridArc expands upon the Dynamic Arc stereotactic treatment technique to offer high dose conformity to the target. The software package uses an adaptive dose calculation matrix that takes into account the different parameters affecting dose distribution to provide precision when opting for stereotactic radiosurgery.

According to Munich-based BrainLab, HybridArc can be deployed in hospitals that either have Linac treatment technology or those that want to gain the capability of radiosurgery without a hardware upgrade. Treatments can be delivered on most Linac-based radiosurgery systems.

TriMed Staff

Related Content

MRI-first approach could allow many to safely forego prostate biopsy
MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.